Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer.

被引：0
|
作者：
Ter-Zakarian, Anna [1 ]
Donovan, Lauren N. [1 ]
Nasraty, Farah [1 ]
机构：
[1] Scripps Clin, La Jolla, CA 92037 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13099
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Abemaciclib for the treatment of brain metastases (BM) secondary to hormone receptor positive (HR+), HER2 negative breast cancer.
    Tolaney, Sara M.
    Lin, Nancy U.
    Thornton, Donald
    Klise, Suzanne
    Costigan, Timothy Michael
    Turner, P. Kellie
    Anders, Carey K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [2] The immunomodulatory impacts of endocrine therapy on host immunity in early-stage hormone receptor positive, HER2 negative breast cancer
    Sammons, Sarah L.
    Dent, Susan Faye
    Chang, Ching-Yi
    Liu, Siyao
    Chan, Isaac
    Weinhold, Kent J.
    Perou, Charles M.
    McDonnell, Donald P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer.
    Naik, Hiten
    Gelmon, Karen A.
    Gondara, Lovedeep
    Diocee, Rekha M.
    Speers, Caroline
    Yerushalmi, Rinat
    Lohrisch, Caroline A.
    LeVasseur, Nathalie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
    Sardesai, Sagar D.
    Kassem, Mahmoud
    Morgan, Evan
    Palettas, Marilly
    Stephens, Julie
    Williams, Nicole Olivia
    Stover, Daniel G.
    Van Deusen, Jeffery
    Wesolowski, Robert
    Lustberg, Maryam B.
    Ramaswamy, Bhuvaneswari
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Targeting HER2 heterogeneity in early-stage breast cancer
    Pernas, Sonia
    Tolaney, Sara M.
    [J]. CURRENT OPINION IN ONCOLOGY, 2020, 32 (06) : 545 - 554
  • [6] Prospective Validation and Characterization of HER2 Positive Circulating Tumor Cells in Patients with HER2 Negative Metastatic Breast Cancer.
    Olson, E. M.
    Flores, L. M.
    Najita, J. S.
    Curley, C.
    Jeong, J.
    Murray, K.
    Savoie, J. J.
    Winer, E. P.
    Krop, I. E.
    [J]. CANCER RESEARCH, 2011, 71
  • [7] Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer
    Fedele, Palma
    Orlando, Laura
    Schiavone, Paola
    Calvani, Nicola
    Caliolo, Chiara
    Quaranta, Annamaria
    Nacci, Angelo
    Cinieri, Saverio
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 94 (03) : 291 - 301
  • [8] Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape
    Redfern, Andrew
    Burslem, Katie
    Woodward, Natasha
    Beith, Jane
    Mccarthy, Nicole
    De Boer, Richard
    Bell, Richard
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 19 - 31
  • [9] The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.
    Bao, Kelvin K. H.
    Sutanto, Leone
    Tse, Shirley S. W.
    Cheung, Ka Man
    Chan, Jeffrey C. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    [J]. CANCER RESEARCH, 2017, 77
12345